Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are ...

Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...

All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

Against an increasingly uncertain market backdrop, industry analysts EY said they are keeping an eye on potential ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...